36 results on '"Rückle T"'
Search Results
2. Protecting groups for the peptide bond: Their use for the synthesis of medium-sized cyclic peptides
- Author
-
Rothe, M., primary, Mattern, R.-H., additional, Fahrenschon-Blum, K., additional, and Rückle, T., additional
- Published
- 1995
- Full Text
- View/download PDF
3. PI3K{gamma} regulates cartilage damage in chronic inflammatory arthritis
- Author
-
Hayer, S, Pundt, N, Peters, M A, Wunrau, C, Kühnel, I, Neugebauer, K, Strietholt, S, Zwerina, J, Korb, A, Penninger, J, Joosten, L A, Gay, S, Rückle, T, Schett, G, Pap, T, University of Zurich, and Schett, G
- Subjects
1303 Biochemistry ,1311 Genetics ,10051 Rheumatology Clinic and Institute of Physical Medicine ,1305 Biotechnology ,1312 Molecular Biology ,610 Medicine & health - Published
- 2009
- Full Text
- View/download PDF
4. Insulin granule recruitment and exocytosis is dependent on p110gamma in insulinoma and human beta-cells.
- Author
-
Pigeau GM, Kolic J, Ball BJ, Hoppa MB, Wang YW, Rückle T, Woo M, Manning Fox JE, MacDonald PE, Pigeau, Gary M, Kolic, Jelena, Ball, Brandon J, Hoppa, Michael B, Wang, Ying W, Rückle, Thomas, Woo, Minna, Manning Fox, Jocelyn E, and MacDonald, Patrick E
- Abstract
Objective: Phosphatidylinositol 3-OH kinase (PI3K) has a long-recognized role in beta-cell mass regulation and gene transcription and is implicated in the modulation of insulin secretion. The role of nontyrosine kinase receptor-activated PI3K isoforms is largely unexplored. We therefore investigated the role of the G-protein-coupled PI3Kgamma and its catalytic subunit p110gamma in the regulation of insulin granule recruitment and exocytosis.Research Design and Methods: The expression of p110gamma was knocked down by small-interfering RNA, and p110gamma activity was selectively inhibited with AS605240 (40 nmol/l). Exocytosis and granule recruitment was monitored by islet perifusion, whole-cell capacitance, total internal reflection fluorescence microscopy, and electron microscopy in INS-1 and human beta-cells. Cortical F-actin was examined in INS-1 cells and human islets and in mouse beta-cells lacking the phosphatase and tensin homolog (PTEN).Results: Knockdown or inhibition of p110gamma markedly blunted depolarization-induced insulin secretion and exocytosis and ablated the exocytotic response to direct Ca(2+) infusion. This resulted from reduced granule localization to the plasma membrane and was associated with increased cortical F-actin. Inhibition of p110gamma had no effect on F-actin in beta-cells lacking PTEN. Finally, the effect of p110gamma inhibition on granule localization and exocytosis could be rapidly reversed by agents that promote actin depolymerization.Conclusions: The G-protein-coupled PI3Kgamma is an important determinant of secretory granule trafficking to the plasma membrane, at least in part through the negative regulation of cortical F-actin. Thus, p110gamma activity plays an important role in maintaining a membrane-docked, readily releasable pool of secretory granules in insulinoma and human beta-cells. [ABSTRACT FROM AUTHOR]- Published
- 2009
- Full Text
- View/download PDF
5. Genetic and pharmacological targeting of phosphoinositide 3-kinase-gamma reduces atherosclerosis and favors plaque stability by modulating inflammatory processes.
- Author
-
Fougerat A, Gayral S, Gourdy P, Schambourg A, Rückle T, Schwarz MK, Rommel C, Hirsch E, Arnal JF, Salles JP, Perret B, Breton-Douillon M, Wymann MP, Laffargue M, Fougerat, Anne, Gayral, Stéphanie, Gourdy, Pierre, Schambourg, Alexia, Rückle, Thomas, and Schwarz, Matthias K
- Published
- 2008
- Full Text
- View/download PDF
6. Importance of phosphoinositide 3-kinase gamma in the host defense against pneumococcal infection.
- Author
-
Maus UA, Backi M, Winter C, Srivastava M, Schwarz MK, Rückle T, Paton JC, Briles D, Mack M, Welte T, Maus R, Bohle RM, Seeger W, Rommel C, Hirsch E, Lohmeyer J, and Preissner KT
- Abstract
Rationale: The pivotal role of phosphoinositide 3-kinase gamma (PI3Kgamma) in leukocyte recruitment makes it an attractive target for immunomodulatory therapy. However, interfering with PI3Kgamma signaling might increase the risk of bacterial infections in humans. Objectives: We hypothesized that deletion or pharmacologic inhibition of PI3Kgamma would impair the lung inflammatory response to the prototypic gram-positive bacterial pathogen Streptococcus pneumoniae. Methods: PI3Kgamma knockout (KO) and wild-type mice were infected with S. pneumoniae or challenged with the pneumococcal virulence factor pneumolysin (PLY), and inflammatory leukocyte recruitment, bacterial pathogen elimination, and resolution/repair processes were determined. Measurements and Main Results: PI3Kgamma KO mice challenged with PLY responded with lung edema and neutrophilic alveolitis, but showed a drop in alveolar macrophages and failed to recruit exudate macrophages when compared with wild-type mice. S. pneumoniae-infected PI3Kgamma KO mice and wild-type mice pretreated with the pharmacologic inhibitor AS-605240 recruited similar numbers of neutrophils but substantially fewer exudate macrophages into their lungs than control animals. They also displayed a significantly reduced lung pneumococcal clearance and showed an impaired resolution/repair process, leading to progressive pneumococcal pneumonia. Conclusions: PI3Kgamma gene deletion or pharmacologic inhibition of PI3Kgamma leads to perturbations of critical innate immune responses of the lung to challenge with S. pneumoniae. These data are of clinical relevance for the treatment of chronic inflammatory diseases where pharmacologic inhibition of PI3Kgamma signaling to attenuate effector cell recruitment may have implications for innate immune surveillance of remote organ systems. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
7. Inactivation of PI3Kgamma and PI3Kdelta distorts T-cell development and causes multiple organ inflammation
- Author
-
Matthias P. Wymann, Bart Vanhaesebroeck, Klaus Okkenhaug, Antonio Bilancio, Hong Ji, Thomas Rückle, Christian Rommel, Felix Rintelen, Emilio Hirsch, Wayne Pearce, Montserrat Camps, Caroline Waltzinger, Dominique Bertschy Meier, Ji, H, Rintelen, F, Waltzinger, C, Bertschy Meier, D, Bilancio, Antonio, Pearce, W, Hirsch, E, Wymann, Mp, Rückle, T, Camps, M, Vanhaesebroeck, B, Okkenhaug, K, and Rommel, C. Vanhaesebroeck B.
- Subjects
Class I Phosphatidylinositol 3-Kinases ,medicine.medical_treatment ,T cell ,Immunology ,Fluorescent Antibody Technique ,Inflammation ,Enzyme-Linked Immunosorbent Assay ,Thymus Gland ,Biology ,Immunoglobulin E ,Biochemistry ,Salivary Glands ,Mice ,Phosphatidylinositol 3-Kinases ,Immune system ,Th2 Cells ,T-Lymphocyte Subsets ,Lymphopenia ,medicine ,Animals ,Class Ib Phosphatidylinositol 3-Kinase ,Secretion ,Cell Proliferation ,Mucous Membrane ,Stomach ,Cell Biology ,Hematology ,Eosinophil ,Flow Cytometry ,Mice, Mutant Strains ,Immunoglobulin A ,Eosinophils ,Isoenzymes ,Thymocyte ,Cytokine ,medicine.anatomical_structure ,Immunoglobulin M ,Immunoglobulin G ,biology.protein ,Cytokines ,medicine.symptom ,Lymphocyte Culture Test, Mixed - Abstract
Mice lacking both the p110gamma and p110delta isoforms display severe impairment of thymocyte development. Here, we show that this phenotype is recapitulated in p110gamma-/-/p110delta(D910A/D910A) (p110gamma(KO)delta(D910A)) mice where the p110delta isoform has been inactivated by a point mutation. Moreover, we have examined the pathological consequences of the p110gammadelta deficiency, which include profound T-cell lymphopenia, T-cell and eosinophil infiltration of mucosal organs, elevated IgE levels, and a skewing toward Th2 immune responses. Using small-molecule selective inhibitors, we demonstrated that in mature T cells, p110delta, but not p110gamma, controls Th1 and Th2 cytokine secretion. Thus, the pathology in the p110gammadelta-deficient mice is likely to be secondary to a developmental block in the thymus that leads to lymphopenia-associated inflammatory responses.
- Published
- 2007
8. Innovation at the Interface between Academia and Industry: The BioMed X Model.
- Author
-
Cristian FB, Tidona C, and Rückle T
- Abstract
In the evolving landscape of biomedical research, the convergence of molecular biology and translational medicine has ushered in a new era of pharmaceutical innovation. This paradigm shift, characterized by significant advances in targeted therapies and gene editing, emphasizes the critical role of integrating academic research - and academic researchers - within industry settings. Contemporary innovation models are moving beyond traditional, corporation-centered frameworks, adopting more open, collaborative approaches. Here, we discuss the challenges and solutions brought about by this new direction in pharma innovation and describe the BioMed X innovation model, a unique open innovation approach that has been growing continuously over the past ten years., (© 2024. The Author(s), under exclusive license to Springer Nature Switzerland AG.)
- Published
- 2024
- Full Text
- View/download PDF
9. Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study.
- Author
-
Hartung HP, Derfuss T, Cree BA, Sormani MP, Selmaj K, Stutters J, Prados F, MacManus D, Schneble HM, Lambert E, Porchet H, Glanzman R, Warne D, Curtin F, Kornmann G, Buffet B, Kremer D, Küry P, Leppert D, Rückle T, and Barkhof F
- Subjects
- Double-Blind Method, Gene Products, env therapeutic use, Humans, Magnetic Resonance Imaging, Treatment Outcome, Antibodies, Monoclonal, Humanized adverse effects, Antibodies, Monoclonal, Humanized therapeutic use, Multiple Sclerosis drug therapy, Multiple Sclerosis, Relapsing-Remitting diagnostic imaging, Multiple Sclerosis, Relapsing-Remitting drug therapy, Multiple Sclerosis, Relapsing-Remitting pathology
- Abstract
Background: The envelope protein of human endogenous retrovirus W (HERV-W-Env) is expressed by macrophages and microglia, mediating axonal damage in chronic active MS lesions., Objective and Methods: This phase 2, double-blind, 48-week trial in relapsing-remitting MS with 48-week extension phase assessed the efficacy and safety of temelimab; a monoclonal antibody neutralizing HERV-W-Env. The primary endpoint was the reduction of cumulative gadolinium-enhancing T1-lesions in brain magnetic resonance imaging (MRI) scans at week 24. Additional endpoints included numbers of T2 and T1-hypointense lesions, magnetization transfer ratio, and brain atrophy. In total, 270 participants were randomized to receive monthly intravenous temelimab (6, 12, or 18 mg/kg) or placebo for 24 weeks; at week 24 placebo-treated participants were re-randomized to treatment groups., Results: The primary endpoint was not met. At week 48, participants treated with 18 mg/kg temelimab had fewer new T1-hypointense lesions ( p = 0.014) and showed consistent, however statistically non-significant, reductions in brain atrophy and magnetization transfer ratio decrease, as compared with the placebo/comparator group. These latter two trends were sustained over 96 weeks. No safety issues emerged., Conclusion: Temelimab failed to show an effect on features of acute inflammation but demonstrated preliminary radiological signs of possible anti-neurodegenerative effects. Current data support the development of temelimab for progressive MS., Trial Registration: CHANGE-MS: ClinicalTrials.gov: NCT02782858, EudraCT: 2015-004059-29; ANGEL-MS: ClinicalTrials.gov: NCT03239860, EudraCT: 2016-004935-18.
- Published
- 2022
- Full Text
- View/download PDF
10. A Single-Dose Combination Study with the Experimental Antimalarials Artefenomel and DSM265 To Determine Safety and Antimalarial Activity against Blood-Stage Plasmodium falciparum in Healthy Volunteers.
- Author
-
McCarthy JS, Rückle T, Elliott SL, Ballard E, Collins KA, Marquart L, Griffin P, Chalon S, and Möhrle JJ
- Subjects
- Adamantane administration & dosage, Adamantane pharmacokinetics, Administration, Oral, Adult, Antimalarials pharmacokinetics, Drug Combinations, Female, Healthy Volunteers, Humans, Malaria, Falciparum metabolism, Malaria, Falciparum parasitology, Male, Middle Aged, Parasitemia metabolism, Parasitemia parasitology, Peroxides pharmacokinetics, Plasmodium falciparum drug effects, Pyrimidines pharmacokinetics, Triazoles pharmacokinetics, Young Adult, Adamantane analogs & derivatives, Antimalarials administration & dosage, Malaria, Falciparum drug therapy, Parasitemia drug therapy, Peroxides administration & dosage, Pyrimidines administration & dosage, Triazoles administration & dosage
- Abstract
Artefenomel and DSM265 are two new compounds that have been shown to be well tolerated and effective when administered as monotherapy malaria treatment. This study aimed to determine the safety, pharmacokinetics, and pharmacodynamics of artefenomel and DSM265 administered in combination to healthy subjects in a volunteer infection study using the Plasmodium falciparum -induced blood-stage malaria model. Thirteen subjects were inoculated with parasite-infected erythrocytes on day 0 and received a single oral dose of artefenomel and DSM265 on day 7. Cohort 1 ( n = 8) received 200 mg artefenomel plus 100 mg DSM265, and cohort 2 ( n = 5) received 200 mg artefenomel plus 50 mg DSM265. Blood samples were collected to measure parasitemia, gametocytemia, and artefenomel-DSM265 plasma concentrations. There were no treatment-related adverse events. The pharmacokinetic profiles of artefenomel and DSM265 were similar to those of the compounds when administered as monotherapy, suggesting no pharmacokinetic interactions. A reduction in parasitemia occurred in all subjects following treatment (log
10 parasite reduction ratios over 48 h [PRR48 ] of 2.80 for cohort 1 and 2.71 for cohort 2; parasite clearance half-lives of 5.17 h for cohort 1 and 5.33 h for cohort 2). Recrudescence occurred in 5/8 subjects in cohort 1 between days 19 and 28 and in 5/5 subjects in cohort 2 between days 15 and 22. Low-level gametocytemia (1 to 330 female gametocytes/ml) was detected in all subjects from day 14. The results of this single-dosing combination study support the further clinical development of the use of artefenomel and DSM265 in combination as a treatment for falciparum malaria. (This study has been registered at ClinicalTrials.gov under identifier NCT02389348.)., (Copyright © 2019 McCarthy et al.)- Published
- 2019
- Full Text
- View/download PDF
11. DSM265 at 400 Milligrams Clears Asexual Stage Parasites but Not Mature Gametocytes from the Blood of Healthy Subjects Experimentally Infected with Plasmodium falciparum .
- Author
-
Collins KA, Rückle T, Elliott S, Marquart L, Ballard E, Chalon S, Griffin P, Möhrle JJ, and McCarthy JS
- Subjects
- Animals, Anopheles, Antimalarials administration & dosage, Antimalarials adverse effects, Antimalarials pharmacokinetics, Female, Half-Life, Healthy Volunteers, Humans, Malaria, Falciparum parasitology, Malaria, Falciparum transmission, Male, Mosquito Vectors, Parasitemia drug therapy, Parasitemia parasitology, Plasmodium falciparum drug effects, Pyrimidines administration & dosage, Pyrimidines adverse effects, Pyrimidines pharmacokinetics, Triazoles administration & dosage, Triazoles adverse effects, Triazoles pharmacokinetics, Young Adult, Antimalarials pharmacology, Malaria, Falciparum drug therapy, Plasmodium falciparum physiology, Pyrimidines pharmacology, Triazoles pharmacology
- Abstract
DSM265 is a novel antimalarial drug in clinical development that acts as a selective inhibitor of Plasmodium dihydroorotate dehydrogenase. In a previous phase 1b study, a single 150-mg dose of DSM265 showed partial efficacy against experimentally induced blood-stage Plasmodium falciparum malaria (IBSM). Pharmacokinetic/pharmacodynamic modeling predicted a human efficacious dose of 340 mg. The primary objectives of the current study were to determine the safety and efficacy of a single oral 400-mg dose of DSM265 against P. falciparum in the IBSM model. Eight healthy participants were inoculated intravenously with 2,800 parasites and treated with DSM265 7 days later. Unexpectedly, one participant did not develop parasitemia during the study. All other participants developed parasitemia, with the complete clearance of asexual parasites occurring following DSM265 treatment. All seven subjects also became gametocytemic. The secondary objectives were to investigate the gametocytocidal and transmission-blocking activity of a second 400-mg dose of DSM265, which was administered 23 days after inoculation. Gametocytes were not cleared by the second dose of DSM265, and transmission-blocking activity could not be determined due to low gametocyte densities. Three DSM265-related adverse events occurred, including a cutaneous rash in one subject on the day of the second DSM265 dose. The results obtained in this study support the prediction of the efficacious dose of DSM265 and provide further evidence that DSM265 is generally safe and well tolerated. In addition, this study confirms preclinical data indicating that DSM265 permits the development and maturation of gametocytes and does not clear mature circulating gametocytes. (This study has been registered at ClinicalTrials.gov under identifier NCT02573857.)., (Copyright © 2019 Collins et al.)
- Published
- 2019
- Full Text
- View/download PDF
12. Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study.
- Author
-
Llanos-Cuentas A, Casapia M, Chuquiyauri R, Hinojosa JC, Kerr N, Rosario M, Toovey S, Arch RH, Phillips MA, Rozenberg FD, Bath J, Ng CL, Cowell AN, Winzeler EA, Fidock DA, Baker M, Möhrle JJ, Hooft van Huijsduijnen R, Gobeau N, Araeipour N, Andenmatten N, Rückle T, and Duparc S
- Subjects
- Adult, Cohort Studies, Dihydroorotate Dehydrogenase, Female, Humans, Malaria, Falciparum immunology, Malaria, Falciparum parasitology, Malaria, Vivax immunology, Malaria, Vivax parasitology, Male, Oxidoreductases Acting on CH-CH Group Donors, Peru, Antimalarials administration & dosage, Malaria, Falciparum drug therapy, Malaria, Vivax drug therapy, Plasmodium falciparum immunology, Pyrimidines administration & dosage, Triazoles administration & dosage
- Abstract
Background: DSM265 is a novel, long-duration inhibitor of plasmodium dihydroorotate dehydrogenase (DHODH) with excellent selectivity over human DHODH and activity against blood and liver stages of Plasmodium falciparum. This study aimed to assess the efficacy of DSM265 in patients with P falciparum or Plasmodium vivax malaria infection., Methods: This proof-of-concept, open-label, phase 2a study was conducted at the Asociación Civil Selva Amazónica in Iquitos, Peru. Patients aged 18-70 years, weighing 45-90 kg, who had clinical malaria (P falciparum or P vivax monoinfection) and fever within the previous 24 h were eligible. Exclusion criteria were clinical or laboratory signs of severe malaria, inability to take oral medicine, and use of other antimalarial treatment in the preceding 14 days. Patients were divided into cohorts of those with P falciparum (cohort a) or P vivax (cohort b) infection. Two initial cohorts received single oral doses of 400 mg DSM265. Patients were followed up for efficacy for 28 days and safety for 35 days. Further cohorts received escalated or de-escalated doses of DSM265, after safety and efficacy assessment of the initial dose. The primary endpoints were the proportion of patients achieving PCR-adjusted adequate clinical and parasitological response (ACPR) by day 14 for patients infected with P falciparum and the proportion of patients achieving a crude cure by day 14 for those infected with P vivax. Cohort success, the criteria for dose escalation, was defined as ACPR (P falciparum) or crude cure (P vivax) in at least 80% of patients in the cohort. The primary analysis was done in the intention-to-treat population (ITT) and the per-protocol population, and safety analyses were done in all patients who received the study drug. This study is registered at ClinicalTrials.gov (NCT02123290)., Findings: Between Jan 12, 2015, and Dec 2, 2015, 45 Peruvian patients (24 with P falciparum [cohort a] and 21 with P vivax [cohort b] infection) were sequentially enrolled. For patients with P falciparum malaria in the per-protocol population, all 11 (100%) in the 400 mg group and eight (80%) of ten in the 250 mg group achieved ACPR on day 14. In the ITT analysis, 11 (85%) of 13 in the 400 mg group and eight (73%) of 11 in the 250 mg group achieved ACPR at day 14. For the patients with P vivax malaria, the primary endpoint was not met. In the per-protocol analysis, none of four patients who had 400 mg, three (50%) of six who had 600 mg, and one (25%) of four who had 800 mg DSM265 achieved crude cure at day 14. In the ITT analysis, none of five in the 400 mg group, three (33%) of nine in the 600 mg group, and one (14%) of seven in the 800 mg group achieved crude cure at day 14. During the 28-day extended observation of P falciparum patients, a resistance-associated mutation in the gene encoding the DSM265 target DHODH was observed in two of four recurring patients. DSM265 was well tolerated. The most common adverse events were pyrexia (20 [44%] of 45) and headache (18 [40%] of 45), which are both common symptoms of malaria, and no patients had any treatment-related serious adverse events or adverse events leading to study discontinuation., Interpretation: After a single dose of DSM265, P falciparum parasitaemia was rapidly cleared, whereas against P vivax, DSM265 showed less effective clearance kinetics. Its long duration of action provides the potential to prevent recurrence of P falciparum after treatment with a single dose, which should be further assessed in future combination studies., Funding: The Global Health Innovative Technology Fund, the Bill & Melinda Gates Foundation, the National Institutes of Health (R01 AI103058), the Wellcome Trust, and the UK Department of International Development., (Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
13. Improved safety margin for embryotoxicity in rats for the new endoperoxide artefenomel (OZ439) as compared to artesunate.
- Author
-
Clark RL, Edwards TL, Longo M, Kinney J, Walker DK, Rhodes J, Clode SA, Rückle T, Wells T, Andenmatten N, and Huber AC
- Subjects
- Adamantane pharmacokinetics, Adamantane toxicity, Animals, Artemisinins toxicity, Benzoxazines toxicity, Dose-Response Relationship, Drug, Female, Fetal Development drug effects, Gestational Age, Heme biosynthesis, Organ Culture Techniques, Organogenesis drug effects, Peroxides pharmacokinetics, Phthalimides toxicity, Rats, Adamantane analogs & derivatives, Antimalarials toxicity, Artesunate toxicity, Embryo, Mammalian drug effects, Peroxides toxicity
- Abstract
Background: Combination medicines including an artemisinin are the mainstay of antimalarial therapy. Artemisinins are potent embryotoxicants in animal species due to their trioxane moiety., Methods: As part of its development, the new synthetic trioxolane antimalarial artefenomel (OZ439) was tested in rat whole embryo culture and in rat embryo-fetal toxicity studies with dosing throughout organogenesis or with a single dose on Gestational Day (GD) 12. The single-dose studies included groups treated with artesunate to allow a direct comparison of the embryotoxicity of the two antimalarials and included toxicokinetics hematology and histological examination of embryos. In addition, the distribution of artefenomel-related material in plasma was determined after the administration of
14 C-artefenomel., Results: Artefenomel and artesunate showed similar patterns of embryotoxicity including cardiovascular defects and resorption with a steep dose-response. They both also caused a depletion of circulating embryonic erythroblasts both in vitro and in vivo and decreases in maternal reticulocyte count. However, artefenomel was ∼250-fold less potent than the active metabolite of artesunate (dihydroartemisinin) as an embryotoxicant in vitro. The safety margin (based on AUC) for artefenomel administered on GD 12 was approximately 100-fold greater than that for artesunate. Also, unlike artesunate, artefenomel was not a selective developmental toxicant., Conclusions: The lesser embryotoxicity of artefenomel is likely linked to its original design which included two blocking side groups that had been introduced to lower the reactivity with ferrous iron. Our data support the hypothesis that artefenomel's improved safety margin is linked to a lower potential for inhibiting heme biosynthesis in embryonic erythroblasts., (© 2017 The Authors. Birth Defects Research Published by Wiley Periodicals, Inc.)- Published
- 2018
- Full Text
- View/download PDF
14. Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study.
- Author
-
McCarthy JS, Lotharius J, Rückle T, Chalon S, Phillips MA, Elliott S, Sekuloski S, Griffin P, Ng CL, Fidock DA, Marquart L, Williams NS, Gobeau N, Bebrevska L, Rosario M, Marsh K, and Möhrle JJ
- Subjects
- Adolescent, Adult, Antimalarials pharmacokinetics, Antimalarials therapeutic use, Australia, Dihydroorotate Dehydrogenase, Double-Blind Method, Enzyme Inhibitors chemistry, Enzyme Inhibitors pharmacokinetics, Half-Life, Humans, Malaria, Falciparum drug therapy, Middle Aged, New Zealand, Oxidoreductases Acting on CH-CH Group Donors, Plasmodium falciparum, Pyrimidines therapeutic use, Triazoles therapeutic use, Antimalarials administration & dosage, Mefloquine therapeutic use, Pyrimidines administration & dosage, Pyrimidines pharmacokinetics, Triazoles administration & dosage, Triazoles pharmacokinetics
- Abstract
Background: DSM265 is a novel antimalarial that inhibits plasmodial dihydroorotate dehydrogenase, an enzyme essential for pyrimidine biosynthesis. We investigated the safety, tolerability, and pharmacokinetics of DSM265, and tested its antimalarial activity., Methods: Healthy participants aged 18-55 years were enrolled in a two-part study: part 1, a single ascending dose (25-1200 mg), double-blind, randomised, placebo-controlled study, and part 2, an open-label, randomised, active-comparator controlled study, in which participants were inoculated with Plasmodium falciparum induced blood-stage malaria (IBSM) and treated with DSM265 (150 mg) or mefloquine (10 mg/kg). Primary endpoints were DSM265 safety, tolerability, and pharmacokinetics. Randomisation lists were created using a validated, automated system. Both parts were registered with the Australian New Zealand Clinical Trials Registry, number ACTRN12613000522718 (part 1) and number ACTRN12613000527763 (part 2)., Findings: In part 1, 73 participants were enrolled between April 12, 2013, and July 14, 2015 (DSM265, n=55; placebo, n=18). In part 2, nine participants were enrolled between Sept 30 and Nov 25, 2013 (150 mg DSM265, n=7; 10 mg/kg mefloquine, n=2). In part 1, 117 adverse events were reported; no drug-related serious or severe events were reported. The most common drug-related adverse event was headache. The mean DSM265 peak plasma concentration (C
max ) ranged between 1310 ng/mL and 34 800 ng/mL and was reached in a median time (tmax ) between 1·5 h and 4 h, with a mean elimination half-life between 86 h and 118 h. In part 2, the log10 parasite reduction ratio at 48 h in the DSM265 (150 mg) group was 1·55 (95% CI 1·42-1·67) and in the mefloquine (10 mg/kg) group was 2·34 (2·17-2·52), corresponding to a parasite clearance half-life of 9·4 h (8·7-10·2) and 6·2 h (5·7-6·7), respectively. The median minimum inhibitory concentration of DSM265 in blood was estimated as 1040 ng/mL (range 552-1500), resulting in a predicted single efficacious dose of 340 mg. Parasite clearance was significantly faster in participants who received mefloquine than in participants who received DSM265 (p<0·0001)., Interpretation: The good safety profile, long elimination half-life, and antimalarial effect of DSM265 supports its development as a partner drug in a single-dose antimalarial combination treatment., Funding: Wellcome Trust, UK Department for International Development, Global Health Innovative Technology Fund, Bill & Melinda Gates Foundation., (Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license. Published by Elsevier Ltd.. All rights reserved.)- Published
- 2017
- Full Text
- View/download PDF
15. DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection.
- Author
-
Sulyok M, Rückle T, Roth A, Mürbeth RE, Chalon S, Kerr N, Samec SS, Gobeau N, Calle CL, Ibáñez J, Sulyok Z, Held J, Gebru T, Granados P, Brückner S, Nguetse C, Mengue J, Lalremruata A, Sim BKL, Hoffman SL, Möhrle JJ, Kremsner PG, and Mordmüller B
- Subjects
- Administration, Intravenous, Adolescent, Adult, Antimalarials therapeutic use, Double-Blind Method, Female, Humans, Malaria, Falciparum immunology, Malaria, Falciparum parasitology, Male, Middle Aged, Parasitemia immunology, Parasitemia parasitology, Pyrimidines therapeutic use, Sporozoites immunology, Triazoles therapeutic use, Volunteers, Antimalarials administration & dosage, Chemoprevention, Malaria, Falciparum drug therapy, Plasmodium falciparum immunology, Pyrimidines administration & dosage, Triazoles administration & dosage
- Abstract
Background: A drug for causal (ie, pre-erythrocytic) prophylaxis of Plasmodium falciparum malaria with prolonged activity would substantially advance malaria control. DSM265 is an experimental antimalarial that selectively inhibits the parasite dihydroorotate dehydrogenase. DSM265 shows in vitro activity against liver and blood stages of P falciparum. We assessed the prophylactic activity of DSM265 against controlled human malaria infection (CHMI)., Methods: At the Institute of Tropical Medicine, Eberhard Karls University (Tübingen, Germany), healthy, malaria-naive adults were allocated to receive 400 mg DSM265 or placebo either 1 day (cohort 1A) or 7 days (cohort 2) before CHMI by direct venous inoculation (DVI) of 3200 aseptic, purified, cryopreserved P falciparum sporozoites (PfSPZ Challenge; Sanaria Inc, Rockville, MD, USA). An additional group received daily atovaquone-proguanil (250-100 mg) for 9 days, starting 1 day before CHMI (cohort 1B). Allocation to DSM265, atovaquone-proguanil, or placebo was randomised by an interactive web response system. Allocation to cohort 1A and 1B was open-label, within cohorts 1A and 2, allocation to DSM265 and placebo was double-blinded. All treatments were given orally. Volunteers were treated with an antimalarial on day 28, or when parasitaemic, as detected by thick blood smear (TBS) microscopy. The primary efficacy endpoint was time-to-parasitaemia, assessed by TBS. All participants receiving at least one dose of chemoprophylaxis or placebo were considered for safety, those receiving PfSPZ Challenge for efficacy analyses. Log-rank test was used to compare time-to-parasitemia between interventions. The trial was registered with ClinicalTrials.gov, number NCT02450578., Findings: 22 participants were enrolled between Oct 23, 2015, and Jan 18, 2016. Five participants received 400 mg DSM265 and two participants received placebo 1 day before CHMI (cohort 1A), six participants received daily atovaquone-proguanil 1 day before CHMI (cohort 1B), and six participants received 400 mg DSM265 and two participants received placebo 7 days before CHMI (cohort 2). Five of five participants receiving DSM265 1 day before CHMI and six of six in the atovaquone-proguanil cohort were protected, whereas placebo recipients (two of two) developed malaria on days 11 and 14. When given 7 days before CHMI, three of six volunteers receiving DSM265 became TBS positive on days 11, 13, and 24. The remaining three DSM265-treated, TBS-negative participants of cohort 2 developed transient submicroscopic parasitaemia. Both participants receiving placebo 7 days before CHMI became TBS positive on day 11. The only possible DSM265-related adverse event was a moderate transient elevation in serum bilirubin in one participant., Interpretation: A single dose of 400 mg DSM265 was well tolerated and had causal prophylactic activity when given 1 day before CHMI. Future trials are needed to investigate further the use of DSM265 for the prophylaxis of malaria., Funding: Global Health Innovative Technology Fund, Wellcome Trust, Bill & Melinda Gates Foundation through Medicines for Malaria Venture, and the German Center for Infection Research., (Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
16. A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study.
- Author
-
McCarthy JS, Rückle T, Djeriou E, Cantalloube C, Ter-Minassian D, Baker M, O'Rourke P, Griffin P, Marquart L, Hooft van Huijsduijnen R, and Möhrle JJ
- Subjects
- Adolescent, Adult, Aminoquinolines pharmacokinetics, Aminoquinolines pharmacology, Antimalarials pharmacokinetics, Antimalarials pharmacology, Blood parasitology, Blood Chemical Analysis, Chromatography, Liquid, Female, Ferrous Compounds pharmacokinetics, Ferrous Compounds pharmacology, Healthy Volunteers, Humans, Male, Metallocenes, Middle Aged, Parasite Load, Plasmodium falciparum isolation & purification, Real-Time Polymerase Chain Reaction, Tandem Mass Spectrometry, Treatment Outcome, Young Adult, Aminoquinolines administration & dosage, Antimalarials administration & dosage, Ferrous Compounds administration & dosage, Malaria, Falciparum drug therapy, Plasmodium falciparum drug effects
- Abstract
Background: Ferroquine (SSR97193) is a candidate anti-malarial currently undergoing clinical trials for malaria. To better understand its pharmacokinetic (PK) and pharmacodynamic (PD) parameters the compound was tested in the experimentally induced blood stage malaria infection model in volunteers., Methods: Male and non-pregnant female aged 18-50 years were screened for this phase II, controlled, single-centre clinical trial. Subjects were inoculated with ~1800 viable Plasmodium falciparum 3D7A-infected human erythrocytes, and treated with a single-dose of 800 mg ferroquine. Blood samples were taken at defined time-points to measure PK and PD parameters. The blood concentration of ferroquine and its active metabolite, SSR97213, were measured on dry blood spot samples by ultra-performance liquid chromatography with tandem mass spectrometry (LC-MS/MS). Parasitaemia and emergence of gametocytes were monitored by quantitative PCR. Safety was determined by recording adverse events and monitoring clinical laboratory assessments during the course of the study., Results: Eight subjects were enrolled into the study, inoculated with infected erythrocytes and treated with 800 mg ferroquine. Ferroquine was rapidly absorbed with maximal exposure after 4-8 and 4-12 h exposure for SSR97213. Non-compartmental PK analysis resulted in estimates for half-lives of 10.9 and 23.8 days for ferroquine and SSR97213, respectively. Parasite clearance as reported by parasite reduction ratio was 162.9 (95 % CI 141-188) corresponding to a parasite clearance half-life of 6.5 h (95 % CI: 6.4-6.7 h). PK/PD modelling resulted in a predicted minimal parasiticidal concentration of 20 ng/mL, and the single dosing tested in this study was predicted to maintain an exposure above this threshold for 454 h (37.8 days). Although ferroquine was overall well tolerated, transient elevated transaminase levels were observed in three subjects. Paracetamol was the only concomitant treatment among the two out of these three subjects that may have played a role in the elevated transaminases levels. No clinically significant ECG abnormalities were observed., Conclusions: The parameters and PK/PD model derived from this study pave the way to the further rational development of ferroquine as an anti-malarial partner drug. The safety of ferroquine has to be further explored in controlled human trials. Trial registration anzctr.org.au (registration number: ACTRN12613001040752), registered 18/09/2013.
- Published
- 2016
- Full Text
- View/download PDF
17. Critical role for phosphoinositide 3-kinase gamma in parasite invasion and disease progression of cutaneous leishmaniasis.
- Author
-
Cummings HE, Barbi J, Reville P, Oghumu S, Zorko N, Sarkar A, Keiser TL, Lu B, Rückle T, Varikuti S, Lezama-Davila C, Wewers MD, Whitacre C, Radzioch D, Rommel C, Seveau S, and Satoskar AR
- Subjects
- Animals, Antimony Sodium Gluconate therapeutic use, Flow Cytometry, Host-Parasite Interactions drug effects, Humans, Leishmaniasis, Cutaneous physiopathology, Macrophages, Mice, Mice, Inbred C57BL, Microscopy, Fluorescence, Neutrophils, Phagocytes drug effects, Phosphoinositide-3 Kinase Inhibitors, Quinoxalines therapeutic use, Thiazolidinediones therapeutic use, Disease Resistance drug effects, Leishmania mexicana, Leishmaniasis, Cutaneous parasitology, Phosphatidylinositol 3-Kinases metabolism, Quinoxalines pharmacology, Thiazolidinediones pharmacology
- Abstract
Obligate intracellular pathogens such as Leishmania specifically target host phagocytes for survival and replication. Phosphoinositide 3-kinase γ (PI3Kγ), a member of the class I PI3Ks that is highly expressed by leukocytes, controls cell migration by initiating actin polymerization and cytoskeletal reorganization, which are processes also critical for phagocytosis. In this study, we demonstrate that class IB PI3K, PI3Kγ, plays a critical role in pathogenesis of chronic cutaneous leishmaniasis caused by L. mexicana. Using the isoform-selective PI3Kγ inhibitor, AS-605240 and PI3Kγ gene-deficient mice, we show that selective blockade or deficiency of PI3Kγ significantly enhances resistance against L. mexicana that is associated with a significant suppression of parasite entry into phagocytes and reduction in recruitment of host phagocytes as well as regulatory T cells to the site of infection. Furthermore, we demonstrate that AS-605240 is as effective as the standard antileishmanial drug sodium stibogluconate in treatment of cutaneous leishmaniasis caused by L. mexicana. These findings reveal a unique role for PI3Kγ in Leishmania invasion and establishment of chronic infection, and demonstrate that therapeutic targeting of host pathways involved in establishment of infection may be a viable strategy for treating infections caused by obligate intracellular pathogens such as Leishmania.
- Published
- 2012
- Full Text
- View/download PDF
18. Regulation of the severity of neuroinflammation and demyelination by TLR-ASK1-p38 pathway.
- Author
-
Guo X, Harada C, Namekata K, Matsuzawa A, Camps M, Ji H, Swinnen D, Jorand-Lebrun C, Muzerelle M, Vitte PA, Rückle T, Kimura A, Kohyama K, Matsumoto Y, Ichijo H, and Harada T
- Subjects
- Animals, Brain Diseases drug therapy, Brain Diseases genetics, Brain Diseases immunology, Brain Diseases metabolism, Chemokines immunology, Demyelinating Diseases drug therapy, Demyelinating Diseases genetics, Demyelinating Diseases immunology, Disease Models, Animal, Encephalitis, Enzyme Inhibitors administration & dosage, Female, Gene Expression Regulation, Hashimoto Disease drug therapy, Hashimoto Disease genetics, Hashimoto Disease immunology, Hashimoto Disease metabolism, Humans, MAP Kinase Kinase Kinase 5 antagonists & inhibitors, MAP Kinase Kinase Kinase 5 genetics, Male, Mice, Mice, Inbred C57BL, Neuroglia metabolism, Rats, Rats, Sprague-Dawley, Toll-Like Receptors genetics, p38 Mitogen-Activated Protein Kinases genetics, Demyelinating Diseases metabolism, MAP Kinase Kinase Kinase 5 metabolism, Signal Transduction, Toll-Like Receptors metabolism, p38 Mitogen-Activated Protein Kinases metabolism
- Abstract
Apoptosis signal-regulating kinase 1 (ASK1) is an evolutionarily conserved mitogen-activated protein kinase (MAPK) kinase kinase which plays important roles in stress and immune responses. Here, we show that ASK1 deficiency attenuates neuroinflammation in experimental autoimmune encephalomyelitis (EAE), without affecting the proliferation capability of T cells. Moreover, we found that EAE upregulates expression of Toll-like receptors (TLRs) in activated astrocytes and microglia, and that TLRs can synergize with ASK1-p38 MAPK signalling in the release of key chemokines from astrocytes. Consequently, oral treatment with a specific small molecular weight inhibitor of ASK1 suppressed EAE-induced autoimmune inflammation in both spinal cords and optic nerves. These results suggest that the TLR-ASK1-p38 pathway in glial cells may serve as a valid therapeutic target for autoimmune demyelinating disorders including multiple sclerosis.
- Published
- 2010
- Full Text
- View/download PDF
19. Isoform-selective phosphoinositide 3-kinase inhibitors induce apoptosis in chronic lymphocytic leukaemia cells.
- Author
-
de Frias M, Iglesias-Serret D, Cosialls AM, González-Gironès DM, Pérez-Perarnau A, Rubio-Patiño C, Rückle T, Camps M, de Sevilla AF, de la Banda E, Pons G, and Gil J
- Subjects
- Dose-Response Relationship, Drug, Humans, Isoenzymes antagonists & inhibitors, Tumor Cells, Cultured, 1-Phosphatidylinositol 4-Kinase antagonists & inhibitors, Antineoplastic Agents pharmacology, Apoptosis drug effects, Enzyme Inhibitors pharmacology, Leukemia, Lymphocytic, Chronic, B-Cell pathology
- Published
- 2010
- Full Text
- View/download PDF
20. Phosphoinositide 3-kinase gamma required for lipopolysaccharide-induced transepithelial neutrophil trafficking in the lung.
- Author
-
Reutershan J, Saprito MS, Wu D, Rückle T, and Ley K
- Subjects
- Analysis of Variance, Animals, Bronchoalveolar Lavage Fluid chemistry, Bronchoalveolar Lavage Fluid cytology, Cell Movement drug effects, Chimera, Class Ib Phosphatidylinositol 3-Kinase, Disease Models, Animal, Flow Cytometry, Humans, Intracellular Signaling Peptides and Proteins immunology, Isoenzymes immunology, Lipopolysaccharides pharmacology, Male, Membrane Proteins immunology, Mice, Quinoxalines pharmacology, Thiazolidinediones pharmacology, Acute Lung Injury immunology, Lung immunology, Neutrophils immunology, Phosphatidylinositol 3-Kinases immunology
- Abstract
Phosphoinositide 3-kinase gamma(PI3Kgamma) is a critical mediator of directional cell movement. Here, we sought to characterise the role of PI3Kgamma in mediating the different steps of polymorphonuclear leukocyte (PMN) trafficking in the lung. In a murine model of lipopolysaccharide (LPS)-induced lung injury, PMN migration into the different lung compartments was determined in PI3Kgamma gene-deficient (PI3Kgamma(-/-)) and wild-type mice. Bone marrow chimeras were created to characterise the role of PI3Kgamma on haematopoietic versus nonhaematopoietic cells. A small-molecule PI3Kgamma inhibitor was tested in vitro and in vivo. PMN adhesion to the pulmonary endothelium and transendothelial migration into the lung interstitium was enhanced in PI3Kgamma(-/-) mice. However, transepithelial migration into the alveolar space was reduced in these mice. When irradiated PI3Kgamma(-/-) mice were reconstituted with bone marrow from wild-type mice, migratory activity into the alveolar space was restored partially. A small-molecule PI3Kgamma inhibitor reduced chemokine-induced PMN migration in vitro when PMNs or epithelial cells, but not when endothelial cells, were treated. The inhibitor also reduced LPS-induced PMN migration in vivo. We conclude that PI3Kgamma is required for transepithelial but not for transendothelial migration in LPS-induced lung injury. Inhibition of PI3Kgamma activity may be effective at curbing excessive PMN infiltration in lung injury.
- Published
- 2010
- Full Text
- View/download PDF
21. The p110delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors.
- Author
-
Berndt A, Miller S, Williams O, Le DD, Houseman BT, Pacold JI, Gorrec F, Hon WC, Liu Y, Rommel C, Gaillard P, Rückle T, Schwarz MK, Shokat KM, Shaw JP, and Williams RL
- Published
- 2010
- Full Text
- View/download PDF
22. The p110 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors.
- Author
-
Berndt A, Miller S, Williams O, Le DD, Houseman BT, Pacold JI, Gorrec F, Hon WC, Liu Y, Rommel C, Gaillard P, Rückle T, Schwarz MK, Shokat KM, Shaw JP, and Williams RL
- Subjects
- Adenosine Triphosphate chemistry, Adenosine Triphosphate metabolism, Animals, Cell Line, Computer Simulation, Crystallography, X-Ray, Humans, Hydrophobic and Hydrophilic Interactions, Models, Molecular, Phosphatidylinositol 3-Kinases metabolism, Protein Interaction Domains and Motifs, Spodoptera, Structure-Activity Relationship, Substrate Specificity, Catalytic Domain, Phosphatidylinositol 3-Kinases chemistry, Protein Kinase Inhibitors chemistry
- Abstract
Deregulation of the phosphoinositide-3-OH kinase (PI(3)K) pathway has been implicated in numerous pathologies including cancer, diabetes, thrombosis, rheumatoid arthritis and asthma. Recently, small-molecule and ATP-competitive PI(3)K inhibitors with a wide range of selectivities have entered clinical development. In order to understand the mechanisms underlying the isoform selectivity of these inhibitors, we developed a new expression strategy that enabled us to determine to our knowledge the first crystal structure of the catalytic subunit of the class IA PI(3)K p110 delta. Structures of this enzyme in complex with a broad panel of isoform- and pan-selective class I PI(3)K inhibitors reveal that selectivity toward p110 delta can be achieved by exploiting its conformational flexibility and the sequence diversity of active site residues that do not contact ATP. We have used these observations to rationalize and synthesize highly selective inhibitors for p110 delta with greatly improved potencies.
- Published
- 2010
- Full Text
- View/download PDF
23. PI3Kgamma regulates cartilage damage in chronic inflammatory arthritis.
- Author
-
Hayer S, Pundt N, Peters MA, Wunrau C, Kühnel I, Neugebauer K, Strietholt S, Zwerina J, Korb A, Penninger J, Joosten LA, Gay S, Rückle T, Schett G, and Pap T
- Subjects
- Animals, Arthritis genetics, Arthritis pathology, Arthritis, Rheumatoid metabolism, Chondrocytes metabolism, Class Ib Phosphatidylinositol 3-Kinase, Extracellular Signal-Regulated MAP Kinases metabolism, Female, Fibroblasts cytology, Fibroblasts metabolism, Gene Expression physiology, Humans, Isoenzymes genetics, Isoenzymes metabolism, Male, Metalloproteases metabolism, Mice, Mice, Knockout, Phosphatidylinositol 3-Kinases genetics, Proto-Oncogene Proteins c-akt metabolism, Synovial Membrane cytology, Time Factors, Tumor Necrosis Factor-alpha metabolism, Arthritis metabolism, Cartilage pathology, Phosphatidylinositol 3-Kinases metabolism
- Abstract
The gamma isoform of phosphoinositide 3-kinase (PI3Kgamma) has been viewed as restricted to leukocytes mediating the regulation of chemokine-induced migration and recruitment of neutrophils, monocytes, and macrophages. In line with the observation that PI3Kgamma-deficient mice display defects in adaptive immunity, inhibition of PI3Kgamma reduces synovial inflammation in the collagen-induced arthritis mouse model of inflammatory arthritis [rheumatoid arthritis (RA)], which has been attributed to reduced influx of inflammatory cells. Challenging the concept of leukocyte-restricted PI3Kgamma function, we report here a novel, nonredundant function of PI3Kgamma as an important regulator of fibroblast-induced cartilage destruction during chronic destructive arthritis. We show that in human tumor necrosis factor transgenic mice, the loss of PI3Kgamma leads to a milder inflammatory arthritis. Interestingly, PI3Kgamma deficiency does not alter the recruitment of inflammatory cells, but significantly reduces cartilage damage through reduced expression of matrix metalloproteinases in fibroblasts and chondrocytes. In vitro analyses demonstrate that the decreased invasiveness of fibroblasts is mediated by reduced phosphorylation of Akt and extracellular signal-regulated kinase. Using a PI3Kgamma specific inhibitor, these data are confirmed in human synovial fibroblasts from patients with RA who exhibit a disease-specific up-regulation of PI3Kgamma. Our data indicate that in addition to mediating the recruitment of inflammatory cells, PI3Kgamma is an important regulator of fibroblast-mediated joint destruction in RA and suggest that specific inhibitors of PI3Kgamma will interfere with the activation of RA synovial fibroblasts and reduce cartilage destruction in RA.
- Published
- 2009
- Full Text
- View/download PDF
24. BMP2 induction of actin cytoskeleton reorganization and cell migration requires PI3-kinase and Cdc42 activity.
- Author
-
Gamell C, Osses N, Bartrons R, Rückle T, Camps M, Rosa JL, and Ventura F
- Subjects
- 3T3 Cells, Animals, Cells, Cultured, Lim Kinases metabolism, Mice, Signal Transduction, Actin Cytoskeleton metabolism, Actins metabolism, Bone Morphogenetic Protein 2 metabolism, Cell Movement physiology, Phosphatidylinositol 3-Kinases metabolism, cdc42 GTP-Binding Protein metabolism
- Abstract
Bone morphogenetic proteins (BMPs) are potent regulators of several cellular events. We report that exposure of C2C12 cells to BMP2 leads to an increase in cell migration and a rapid rearrangement of the actin filaments into cortical protrusions. These effects required independent and parallel activation of the Cdc42 small GTPase and the alpha-isoform of the phosphoinositide 3-kinase (PI3Kalpha), because ectopic expression of a dominant-negative form of Cdc42 or distinct pharmacological PI3K inhibitors abrogated these responses. Furthermore, we demonstrate that BMP2 activates different group I and group II PAK isoforms as well as LIMK1 with similar kinetics to Cdc42 or PI3K activation. BMP2 activation of PAK and LIMK1, measured by either kinase activity or with antibodies raised against phosphorylated residues at their activation loops, were abolished by blocking PI3K-signaling pathways. Together, these findings suggest that Cdc42 and PI3K signals emanating from BMP receptors are involved in specific regulation of actin assembly and cell migration.
- Published
- 2008
- Full Text
- View/download PDF
25. PI3Kgamma (PI3Kgamma) is essential for efficient induction of CXCR3 on activated T cells.
- Author
-
Barbi J, Cummings HE, Lu B, Oghumu S, Rückle T, Rommel C, Lafuse W, Whitacre CC, and Satoskar AR
- Subjects
- Androstadienes pharmacology, Animals, Chemotaxis, Chromones pharmacology, Class Ib Phosphatidylinositol 3-Kinase, Isoenzymes genetics, Isoenzymes metabolism, Isoenzymes physiology, Leishmaniasis metabolism, Leukocytes cytology, Mice, Mice, Inbred C57BL, Mice, Transgenic, Morpholines pharmacology, Phosphatidylinositol 3-Kinases metabolism, Protein Kinase Inhibitors pharmacology, RNA, Small Interfering metabolism, T-Lymphocytes parasitology, Wortmannin, Phosphatidylinositol 3-Kinases genetics, Phosphatidylinositol 3-Kinases physiology, Receptors, CXCR3 metabolism, T-Lymphocytes metabolism, Up-Regulation
- Abstract
The gamma isoform of PI3Kinase (PI3Kgamma) controls leukocyte chemotaxis by participating in GPCR signaling, and by regulating cellular polarization. Here we show that PI3Kgamma is required for efficient induction of CXC chemokine receptor 3 (CXCR3) on T cells upon activation. T cells from PI3Kgamma(-/-) mice up-regulated CXCR3 less efficiently than wild-type controls both upon activation in vitro as well as during Leishmania mexicana infection. Inhibition of PI3Kinases using wortmannin and LY294002 or blockade of PI3Kgamma activity using a selective inhibitor or PI3Kgamma siRNA suppressed induction of CXCR3 on T cells following activation. Levels of CXCR3 and T-bet mRNA were significantly lower in PI3Kgamma inhibitor-treated T cells, indicating that PI3Kgamma may control CXCR3 expression in part through induction of T-bet. These results reveal a novel role for PI3Kgamma in the induction of CXCR3 on T cells and suggest that PI3Kgamma may regulate leukocyte chemotaxis by controlling the expression of chemokine receptors.
- Published
- 2008
- Full Text
- View/download PDF
26. Phosphoinositide 3-kinase p110beta activity: key role in metabolism and mammary gland cancer but not development.
- Author
-
Ciraolo E, Iezzi M, Marone R, Marengo S, Curcio C, Costa C, Azzolino O, Gonella C, Rubinetto C, Wu H, Dastrù W, Martin EL, Silengo L, Altruda F, Turco E, Lanzetti L, Musiani P, Rückle T, Rommel C, Backer JM, Forni G, Wymann MP, and Hirsch E
- Subjects
- Aging physiology, Animals, Cell Transformation, Neoplastic metabolism, Cell Transformation, Neoplastic pathology, Cells, Cultured, Class I Phosphatidylinositol 3-Kinases, Endocytosis, Mammary Neoplasms, Experimental pathology, Mice, Mice, Mutant Strains, Phosphatidylinositol 3-Kinases genetics, Receptor, ErbB-2 physiology, Signal Transduction, Diabetes Mellitus, Experimental enzymology, Insulin Resistance physiology, Mammary Neoplasms, Experimental enzymology, Phosphatidylinositol 3-Kinases physiology
- Abstract
The phosphoinositide 3-kinase (PI3K) pathway crucially controls metabolism and cell growth. Although different PI3K catalytic subunits are known to play distinct roles, the specific in vivo function of p110beta (the product of the PIK3CB gene) is not clear. Here, we show that mouse mutants expressing a catalytically inactive PIK3CB(K805R) mutant survived to adulthood but showed growth retardation and developed mild insulin resistance with age. Pharmacological and genetic analyses of p110beta function revealed that p110beta catalytic activity is required for PI3K signaling downstream of heterotrimeric guanine nucleotide-binding protein (G protein)-coupled receptors as well as to sustain long-term insulin signaling. In addition, PIK3CB(K805R) mice were protected in a model of ERBB2-driven tumor development. These findings indicate an unexpected role for p110beta catalytic activity in diabetes and cancer, opening potential avenues for therapeutic intervention.
- Published
- 2008
- Full Text
- View/download PDF
27. Isoform-specific functions of phosphoinositide 3-kinases: p110 delta but not p110 gamma promotes optimal allergic responses in vivo.
- Author
-
Ali K, Camps M, Pearce WP, Ji H, Rückle T, Kuehn N, Pasquali C, Chabert C, Rommel C, and Vanhaesebroeck B
- Subjects
- Animals, Catalytic Domain drug effects, Catalytic Domain genetics, Cell Degranulation drug effects, Cell Degranulation immunology, Cells, Cultured, Class I Phosphatidylinositol 3-Kinases, Epitopes physiology, Hypersensitivity genetics, Hypersensitivity pathology, Immunoglobulin E physiology, Inflammation Mediators administration & dosage, Inflammation Mediators pharmacology, Isoenzymes antagonists & inhibitors, Isoenzymes genetics, Isoenzymes physiology, MAP Kinase Signaling System drug effects, MAP Kinase Signaling System genetics, Male, Mast Cells drug effects, Mast Cells enzymology, Mast Cells immunology, Mice, Mice, Inbred C57BL, Mice, Knockout, Phosphatidylinositol 3-Kinases genetics, Phosphoinositide-3 Kinase Inhibitors, Protein Kinase Inhibitors administration & dosage, Protein Kinase Inhibitors pharmacology, Proto-Oncogene Proteins c-akt deficiency, Proto-Oncogene Proteins c-akt genetics, Proto-Oncogene Proteins c-akt metabolism, Receptors, IgG physiology, Hypersensitivity enzymology, Hypersensitivity immunology, Phosphatidylinositol 3-Kinases physiology
- Abstract
The leukocyte-enriched p110gamma and p110delta isoforms of PI3K have been shown to control in vitro degranulation of mast cells induced by cross-linking of the high affinity receptor of IgE (FcepsilonRI). However, the relative contribution of these PI3K isoforms in IgE-dependent allergic responses in vivo is controversial. A side-by-side comparative analysis of the role of p110gamma and p110delta in mast cell function, using genetic approaches and newly developed isoform-selective pharmacologic inhibitors, confirms that both PI3K isoforms play an important role in FcepsilonRI-activated mast cell degranulation in vitro. In vivo, however, only p110delta was found to be required for optimal IgE/Ag-dependent hypersensitivity responses in mice. These observations identify p110delta as a key therapeutic target among PI3K isoforms for allergy- and mast cell-related diseases.
- Published
- 2008
- Full Text
- View/download PDF
28. Inactivation of PI3Kgamma and PI3Kdelta distorts T-cell development and causes multiple organ inflammation.
- Author
-
Ji H, Rintelen F, Waltzinger C, Bertschy Meier D, Bilancio A, Pearce W, Hirsch E, Wymann MP, Rückle T, Camps M, Vanhaesebroeck B, Okkenhaug K, and Rommel C
- Subjects
- Animals, Cell Proliferation, Class I Phosphatidylinositol 3-Kinases, Class Ib Phosphatidylinositol 3-Kinase, Cytokines biosynthesis, Enzyme-Linked Immunosorbent Assay, Eosinophils metabolism, Flow Cytometry, Fluorescent Antibody Technique, Immunoglobulin A blood, Immunoglobulin E blood, Immunoglobulin G blood, Immunoglobulin M blood, Inflammation etiology, Isoenzymes deficiency, Isoenzymes immunology, Lymphocyte Culture Test, Mixed, Lymphopenia etiology, Mice, Mice, Mutant Strains, Mucous Membrane immunology, Mucous Membrane pathology, Phosphatidylinositol 3-Kinases immunology, Salivary Glands immunology, Salivary Glands pathology, Stomach immunology, Stomach pathology, T-Lymphocyte Subsets cytology, T-Lymphocyte Subsets immunology, Thymus Gland immunology, Thymus Gland pathology, Inflammation immunology, Phosphatidylinositol 3-Kinases deficiency, Th2 Cells cytology, Th2 Cells immunology
- Abstract
Mice lacking both the p110gamma and p110delta isoforms display severe impairment of thymocyte development. Here, we show that this phenotype is recapitulated in p110gamma-/-/p110delta(D910A/D910A) (p110gamma(KO)delta(D910A)) mice where the p110delta isoform has been inactivated by a point mutation. Moreover, we have examined the pathological consequences of the p110gammadelta deficiency, which include profound T-cell lymphopenia, T-cell and eosinophil infiltration of mucosal organs, elevated IgE levels, and a skewing toward Th2 immune responses. Using small-molecule selective inhibitors, we demonstrated that in mature T cells, p110delta, but not p110gamma, controls Th1 and Th2 cytokine secretion. Thus, the pathology in the p110gammadelta-deficient mice is likely to be secondary to a developmental block in the thymus that leads to lymphopenia-associated inflammatory responses.
- Published
- 2007
- Full Text
- View/download PDF
29. Phosphoinositide 3-kinase gamma inhibition plays a crucial role in early steps of inflammation by blocking neutrophil recruitment.
- Author
-
Ferrandi C, Ardissone V, Ferro P, Rückle T, Zaratin P, Ammannati E, Hauben E, Rommel C, and Cirillo R
- Subjects
- Administration, Oral, Animals, Biological Availability, Chemokine CCL5 pharmacology, Class Ib Phosphatidylinositol 3-Kinase, Enzyme Inhibitors administration & dosage, Enzyme Inhibitors pharmacokinetics, Isoenzymes antagonists & inhibitors, Mice, Peritoneum, Chemotaxis drug effects, Enzyme Inhibitors pharmacology, Inflammation drug therapy, Neutrophils drug effects, Phosphoinositide-3 Kinase Inhibitors
- Abstract
Leukocyte trafficking to inflammatory sites is a gradual process, which is dominated in its early phases by chemokine- and cytokine-mediated neutrophil recruitment. The chemokine regulated on activation normal T cell expressed and secreted (RANTES) has been shown to be highly expressed in the joints of patient with rheumatoid arthritis and to promote leukocyte trafficking into the synovial tissue. In this study, we investigated the effect of RANTES in a murine model of peritoneal chemotaxis, and we found that RANTES dose-dependently induces neutrophil recruitment. Then, through morphological and histological analyses, we observed that activated neutrophils represent the major infiltrating population in response to RANTES chemotactic stimulus. Furthermore, we demonstrated that oral administration of either nonisoform-specific phosphoinositide 3-kinase (PI3K) inhibitor LY294002 (morpholin-4-yl-8-phenylchromen-4-one) or selective PI3Kgamma inhibitor AS041164 (5-benzo[1,3]dioxol-5-ylmethylene-thiazolidine-2,4-dione) blocks RANTES-induced chemotaxis and reduces the level of AKT phosphorylation. Because the two compounds showed a similar pharmacokinetic profile in terms of bioavailability and half-life after oral route administration, the selective inhibition of the PI3Kgamma-isoform pathway through AS041164 was three times more potent in reducing neutrophil recruitment. Finally, to confirm the blockade of neutrophil infiltration that occurs in the early phase of the inflammatory response, AS041164 was also tested in a model of carrageenan-induced paw edema in rats. Therefore, the PI3Kgamma pathway plays an important role in controlling neutrophil chemotaxis during early steps of inflammation.
- Published
- 2007
- Full Text
- View/download PDF
30. PI3Kgamma inhibition: towards an 'aspirin of the 21st century'?
- Author
-
Rückle T, Schwarz MK, and Rommel C
- Subjects
- Animals, Chemokines physiology, Hematopoiesis drug effects, Humans, Mice, Receptors, Chemokine drug effects, Receptors, Chemokine physiology, Anti-Inflammatory Agents, Non-Steroidal pharmacology, Aspirin pharmacology, Enzyme Inhibitors pharmacology, Phosphoinositide-3 Kinase Inhibitors
- Abstract
Class IB phosphatidylinositol 3-kinase p110gamma (PI3Kgamma) has gained increasing attention as a promising drug target for the treatment of inflammatory disease. Extensive target-validation data are available, which are derived from studies using both pharmacological and genetic tools. More recent findings have uncovered further therapeutic applications for PI3Kgamma inhibitors, opening up potentially huge opportunities for these drugs. Several companies have been pursuing small-molecule PI3Kgamma inhibitor projects, but none of them has progressed to the clinic yet. Here, we discuss the insights gained so far and the main challenges that are emerging on the path to developing PI3Kgamma inhibitors for the treatment of human disease.
- Published
- 2006
- Full Text
- View/download PDF
31. Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
- Author
-
Pomel V, Klicic J, Covini D, Church DD, Shaw JP, Roulin K, Burgat-Charvillon F, Valognes D, Camps M, Chabert C, Gillieron C, Françon B, Perrin D, Leroy D, Gretener D, Nichols A, Vitte PA, Carboni S, Rommel C, Schwarz MK, and Rückle T
- Subjects
- Acute Disease, Animals, Bone Marrow Cells drug effects, Bone Marrow Cells physiology, Cells, Cultured, Chemotaxis drug effects, Class Ib Phosphatidylinositol 3-Kinase, Crystallography, X-Ray, Furans chemistry, Furans pharmacology, Humans, Isoenzymes antagonists & inhibitors, Isoenzymes chemistry, Mast Cells drug effects, Mast Cells metabolism, Mice, Models, Molecular, Molecular Structure, Monocytes drug effects, Monocytes physiology, Neutrophils immunology, Peritonitis chemically induced, Peritonitis drug therapy, Peritonitis immunology, Phosphatidylinositol 3-Kinases chemistry, Phosphorylation, Proto-Oncogene Proteins c-akt metabolism, Structure-Activity Relationship, Thiazolidinediones chemistry, Thiazolidinediones pharmacology, Thioglycolates, Furans chemical synthesis, Phosphoinositide-3 Kinase Inhibitors, Thiazolidinediones chemical synthesis
- Abstract
Class I phosphoinositide 3-kinases (PI3Ks), in particular PI3Kgamma, have become attractive drug targets for inflammatory and autoimmune diseases. Here, we disclose a novel series of furan-2-ylmethylene thiazolidinediones as selective, ATP-competitive PI3Kgamma inhibitors. Structure-based design and X-ray crystallography of complexes formed by inhibitors bound to PI3Kgamma identified key pharmacophore features for potency and selectivity. An acidic NH group on the thiazolidinedione moiety and a hydroxy group on the furan-2-yl-phenyl part of the molecule play crucial roles in binding to PI3K and contribute to class IB PI3K selectivity. Compound 26 (AS-252424), a potent and selective small-molecule PI3Kgamma inhibitor emerging from these efforts, was further profiled in three different cellular PI3K assays and shown to be selective for class IB PI3K-mediated cellular effects. Oral administration of 26 in a mouse model of acute peritonitis led to a significant reduction of leukocyte recruitment.
- Published
- 2006
- Full Text
- View/download PDF
32. PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus.
- Author
-
Barber DF, Bartolomé A, Hernandez C, Flores JM, Redondo C, Fernandez-Arias C, Camps M, Rückle T, Schwarz MK, Rodríguez S, Martinez-A C, Balomenos D, Rommel C, and Carrera AC
- Subjects
- Animals, Disease Models, Animal, Female, Male, Mice, Mice, Mutant Strains, Enzyme Inhibitors therapeutic use, Lupus Erythematosus, Systemic drug therapy, Lupus Nephritis prevention & control, Phosphoinositide-3 Kinase Inhibitors, Quinoxalines pharmacology, Thiazolidinediones pharmacology
- Abstract
Systemic lupus erythematosus (SLE) is a chronic inflammatory disease generated by deregulation of T cell-mediated B-cell activation, which results in glomerulonephritis and renal failure. Disease is treated with immunosuppressants and cytostatic agents that have numerous side effects. Here we examine the use of inhibitors of phosphoinositide 3-kinase (PI3K) gamma, a lipid kinase that regulates inflammation, in the MRL-lpr mouse model of SLE. Treatment reduced glomerulonephritis and prolonged lifespan, suggesting that P13Kgamma may be a useful target in the treatment of chronic inflammation.
- Published
- 2005
- Full Text
- View/download PDF
33. Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis.
- Author
-
Camps M, Rückle T, Ji H, Ardissone V, Rintelen F, Shaw J, Ferrandi C, Chabert C, Gillieron C, Françon B, Martin T, Gretener D, Perrin D, Leroy D, Vitte PA, Hirsch E, Wymann MP, Cirillo R, Schwarz MK, and Rommel C
- Subjects
- Animals, Arthritis, Rheumatoid chemically induced, Binding Sites, Chemotaxis, Leukocyte drug effects, Dioxoles chemistry, Disease Models, Animal, Isoenzymes, Mice, Mice, Inbred BALB C, Mice, Inbred C3H, Mice, Inbred DBA, Mice, Knockout, Molecular Sequence Data, Molecular Structure, Peritonitis chemically induced, Peritonitis drug therapy, Phosphatidylinositol 3-Kinases chemistry, Quinoxalines chemistry, Signal Transduction, Structure-Activity Relationship, Thiazolidinediones chemistry, Arthritis, Rheumatoid drug therapy, Dioxoles therapeutic use, Enzyme Inhibitors therapeutic use, Phosphoinositide-3 Kinase Inhibitors, Quinoxalines therapeutic use, Thiazolidinediones therapeutic use
- Abstract
Phosphoinositide 3-kinases (PI3K) have long been considered promising drug targets for the treatment of inflammatory and autoimmune disorders as well as cancer and cardiovascular diseases. But the lack of specificity, isoform selectivity and poor biopharmaceutical profile of PI3K inhibitors have so far hampered rigorous disease-relevant target validation. Here we describe the identification and development of specific, selective and orally active small-molecule inhibitors of PI3Kgamma (encoded by Pik3cg). We show that Pik3cg(-/-) mice are largely protected in mouse models of rheumatoid arthritis; this protection correlates with defective neutrophil migration, further validating PI3Kgamma as a therapeutic target. We also describe that oral treatment with a PI3Kgamma inhibitor suppresses the progression of joint inflammation and damage in two distinct mouse models of rheumatoid arthritis, reproducing the protective effects shown by Pik3cg(-/-) mice. Our results identify selective PI3Kgamma inhibitors as potential therapeutic molecules for the treatment of chronic inflammatory disorders such as rheumatoid arthritis.
- Published
- 2005
- Full Text
- View/download PDF
34. Design, synthesis, and biological activity of novel, potent, and selective (benzoylaminomethyl)thiophene sulfonamide inhibitors of c-Jun-N-terminal kinase.
- Author
-
Rückle T, Biamonte M, Grippi-Vallotton T, Arkinstall S, Cambet Y, Camps M, Chabert C, Church DJ, Halazy S, Jiang X, Martinou I, Nichols A, Sauer W, and Gotteland JP
- Subjects
- Animals, Cells, Cultured, Enzyme Inhibitors pharmacology, Structure-Activity Relationship, Sulfonamides pharmacology, Thiophenes pharmacology, Drug Design, Enzyme Inhibitors chemical synthesis, JNK Mitogen-Activated Protein Kinases antagonists & inhibitors, Neuroprotective Agents pharmacology, Sulfonamides chemical synthesis, Thiophenes chemical synthesis
- Abstract
Several lines of evidence support the hypothesis that c-Jun N-terminal kinases (JNKs) play a critical role in a wide range of disease states including cell death (apoptosis)-related and inflammatory disorders (epilepsy, brain, heart and renal ischemia, neurodegenerative diseases, multiple sclerosis, rheumatoid arthritis, and inflammatory bowel syndrome). The screening of a compound collection led to the identification of a 2-(benzoylaminomethyl)thiophene sulfonamide (AS004509, compound I) as a potent and selective JNK inhibitor. Chemistry and structure--activity relationship (SAR) studies performed around this novel kinase-inhibiting motif indicated that the left and central parts of the molecule were instrumental to maintaining potency at the enzyme. Accordingly, we investigated the JNK-inhibiting properties of a number of variants of the right-hand moiety of the molecule, which led to the identification of 2-(benzoylaminomethyl)thiophene sulfonamide benzotriazole (AS600292, compound 50a), the first potent and selective JNK inhibitor of this class which demonstrates a protective action against neuronal cell death induced by growth factor and serum deprivation.
- Published
- 2004
- Full Text
- View/download PDF
35. Mapping of synergistic components of weakly interacting protein-protein motifs using arrays of paired peptides.
- Author
-
Espanel X, Wälchli S, Rückle T, Harrenga A, Huguenin-Reggiani M, and Hooft van Huijsduijnen R
- Subjects
- Combinatorial Chemistry Techniques, Humans, Mitogen-Activated Protein Kinase 1 metabolism, Mutation, Oligopeptides chemical synthesis, Phosphorylation, Protein Binding, Protein Structure, Tertiary, Protein Tyrosine Phosphatase, Non-Receptor Type 1, Protein Tyrosine Phosphatases metabolism, Proto-Oncogene Proteins metabolism, Receptor, Insulin metabolism, Serine metabolism, ets-Domain Protein Elk-1, DNA-Binding Proteins, Oligopeptides metabolism, Peptide Mapping methods, Transcription Factors
- Abstract
Protein-protein recognition usually involves multiple interactions among different motifs that are scattered over protein surfaces. To identify such weak interactions, we have developed a novel double peptide synthesis (DS) method. This method allows us to map protein-protein interactions that involve two linear dis- continuous components from a polypeptide by the use of spatially addressable synergistic pairs of synthetic peptides. The DS procedure is based on the "SPOT" membrane-bound peptide synthesis technique, but to synthesize a mixture of two peptides, it uses both Fmoc (N-(9-fluorenyl)methoxycarbonyl))-alanine and Alloc-alanine at the first cycle. This allows their selective deprotection by either piperidine or tributyltin/palladium treatment, respectively. Using SPOT DS, we confirmed as a proof of principle that Elk-1 Ser(383) phosphorylation by ERK-2 kinase is stimulated by the presence of the Elk-1-docking domain. SPOT DS can also be used to dissect protein-protein motifs that define phosphatase substrate affinity. Using this technique, we identified three new regions in the insulin receptor that stimulate the dephosphorylation of the receptor by protein-tyrosine phosphatase (PTP) 1B and presumably increase the selectivity of PTP for this substrate. These data demonstrate that the SPOT DS technique allows the identification of non-linear weakly interacting protein motifs, which are an important determinant of protein kinase and phosphatase substrate specificity and of protein-protein interactions in general.
- Published
- 2003
- Full Text
- View/download PDF
36. Crystal structure of a synthetic cyclodecapeptide for template-assembled synthetic protein design.
- Author
-
Peluso S, Rückle T, Lehmann C, Mutter M, Peggion C, and Crisma M
- Subjects
- Crystallization, Crystallography, X-Ray, Magnetic Resonance Spectroscopy methods, Molecular Structure, Peptides, Cyclic chemical synthesis, Protein Conformation, Protein Structure, Tertiary, Peptides, Cyclic chemistry
- Abstract
The structural prototype of a new generation of regioselectively addressable functionalized templates (RAFTs) for use in protein de novo design has been synthesized and crystallized. The structure of the aromatically substituted cyclodecapeptide was determined by X-ray diffraction; it consists of an antiparallel beta sheet spanned by heterochirally induced type IIprime prime or minute beta turns, similar to that observed in gramicidin S. The three-dimensional structure of the artificial template was also examined by an NMR spectroscopic analysis in solution and shown to be compatible with a beta-sheet plane suitable for accommodating secondary functional peptide fragments for the synthesis of template-assembled synthetic proteins (TASPs).
- Published
- 2001
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.